Status:
COMPLETED
A Study of Evacetrapib (LY2484595) in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to measure and compare the amounts of the study drug evacetrapib found in the blood after taking two different formulations. The study has 3 periods. Participants will tak...
Eligibility Criteria
Inclusion
- Male participants who agree to use a reliable method of birth control and not donate sperm during the study and for 90 days after study completion
- Female participants who are not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
- Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2)
- Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion
- Are currently enrolled in or have completed or discontinued within the last 30 days from a clinical trial involving an investigational product
- Have known allergies to evacetrapib, related compounds or any components of the formulation, or history of significant allergic disease as determined by the investigator
- Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
- Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- Are women who are pregnant or lactating
- Have used or intend to use over-the-counter or prescription medications (including vitamins/mineral supplements, herbal medicine) 14 days prior to enrollment and during the study
- Have donated blood of more than 500 milliliters (mL) within the last month
- Have an average weekly alcohol intake that exceeds 21 units per week (for males) and 14 units per week (for females) or are unwilling to stop alcohol consumption 48 hours prior to each dose and while resident at the Clinical Research Unit (CRU)
- Currently smoke or use tobacco or nicotine products
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01903434
Start Date
July 1 2013
End Date
November 1 2013
Last Update
October 9 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Evansville, Indiana, United States, 47710